Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Sponsor: National Cancer Institute (NCI)
Listed as NCT02203526, this observational or N/A phase trial focuses on Primary Central Nervous System Lymphoma and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 74 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)Background: * Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included high dose methotrexate and radiation treatment. * Most PCNSLs appear to be of activated B-cell (ABC) origin * Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) and effective for systemic DLBCL of ABC origin. * We propose doing a study in which ibrutinib is combined with a novel chemotherapy platform called temozolomide, etoposide, doxil, dexamethasone, ibrutinib, rituximab (TEDDI-R). Objective: * To identify the dose of ibrutinib with anti-fungal prophylaxis that can be safely administered to achieve an ibrutinib median CSF CMAX of 1.98 nM (Range 0.69 to 11.1) * To assess the safety, feasibility, and complete response (CR) rate of the TEDDI-R in untreated PCNSL (DLBCL type) patients. Eligibility: * Relapsed/refractory or untreated PCNSL * Age \>= 18 years. * No pregnant or nursing individuals. * Adequate organ function (defined in protocol). Study Design: * This is a phase 1 study of 93 patients. * The study will have three components. * Phase 1: MTD of ibrutinib will be...
Background:
* Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included high dose methotrexate and radiation treatment. * Most PCNSLs appear to be of activated B-cell (ABC) origin * Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) and effective for systemic DLBCL of ABC origin. * We propose doing a study in which ibrutinib is combined with a novel chemotherapy platform called temozolomide, etoposide, doxil, dexamethasone, ibrutinib, rituximab (TEDDI-R).
Objective:
* To identify the dose of ibrutinib with anti-fungal prophylaxis that can be safely administered to achieve an ibrutinib median CSF CMAX of 1.98 nM (Range 0.69 to 11.1) * To assess the safety, feasibility, and complete response (CR) rate of the TEDDI-R in untreated PCNSL (DLBCL type) patients.
Eligibility:
* Relapsed/refractory or untreated PCNSL * Age \>= 18 years. * No pregnant or nursing individuals. * Adequate organ function (defined in protocol).
Study Design:
* This is a phase 1 study of 93 patients. * The study will have three components.
* Phase 1: MTD of ibrutinib will be identified or the dose at which ibrutinib achieves a concentration of \>= 100 nM in the CSF, when given in combination with TEDDI-R immuno-chemotherapy, whichever comes first. * Expansion cohort: Safety and tolerability of the regimen in relapsed/refractory PCNSL (DLBCL type) will be assessed at the final ibrutinib dose with TEDDI-R in 10 patients. Secondary objectives will be PFS and OS. * Revised Study Design: new ibrutinib dose levels are being added together with anti-fungal prophylaxis to determine the dose of ibrutinib that may be safely given with the chemotherapy platform. * A second expansion cohort of untreated PCNSL (DLBCL type) will be added: Safety, feasibility, and complete response rate of the regimen in untreated PCNSL (DLBCL type) will be assessed at the final ibrutinib dose with TEDDI-R in 15 patients. Secondary objectives will be PFS and OS. * A new dosing schedule will be tested in up to 10 relapsed or refractory patients and 15 patients with untreated PCNSL. Secondary objectives will be PFS and OS.
Status Flow
Change History
74 versions recorded-
Apr 28, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: PHASE1 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1
▶ Show 69 earlier versions
-
Oct 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Dec 2020 [monthly]
Recruiting PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE1
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
Apr 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1
-
Aug 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
May 2019 — Aug 2019 [monthly]
Recruiting PHASE1
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE1
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
May 2017 — Feb 2018 [monthly]
Suspended PHASE1
-
Feb 2017 — May 2017 [monthly]
Suspended PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
BACKGROUND: * Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma. * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included high dose methotrexate and radiation treatment. * Most PCNSLs appear to be of activated B-cell (ABC) origin. * Ibrutinib is an inhibitor of Bruton s tyrosine kinase (BTK) and effective for systemic DLBCL of ABC origin. * We propose doing a study in which ibrutinib is combined with a novel chemotherapy platform called dose adjusted temozolomide, etoposide, doxil, dexamethasone, ibrutinib, rituximab (TEDDI-R). OBJECTIVE: \- Identify the maximum tolerated dose (MTD) of ibrutinib or the dose that achieves adequate CSF concentrations, whichever comes first, when ibrutinib is given with TEDDI-R. ELIGIBILITY: * Relapsed/refractory PCNSL. * Age greater than or equal to 18 years. * No pregnant or breast-feeding women. * Adequate organ function (defined in protocol). STUDY DESIGN: * This is a phase 1 study of 40 patients. * The study will have two components. 1. Phase 1: MTD of ibrutinib will be identified or the dose at which ibrutinib achieves a concentration of less than or equal to 100 nM in the CSF, when given in combination with TEDDI-R immuno-chemotherapy, whichever comes first. 2. Expansion cohort: Safety and tolerability of the regimen in relapsed/refractory or previously untreated PCNSL (DLBCL type) will be assessed at the final ibrutinib dose with TEDDI-R in 10 patients. Secondary objectives will be PFS and OS.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .